Zurich – Occlufit has received investment from the UZH Life Sciences Fund. The medtech startup is developing a cardiovascular occluder with an adaptable shape.
According to the World Health Organization, more than 17.9 million people die from cardiovascular diseases each year. Most deaths are caused by heart attacks and strokes.
Cardiovascular occluders can help in the detection of cardiovascular disease. No operation is needed, as these devices can be inserted via catheters to repair cardiovascular defects. Until now, occluders have only been available in standard sizes. Occlufit has designed an adaptable cardiovascular occluder device that fits the varied anatomy of individual patients.
Occlufit has now secured an investment from the UZH Life Sciences Fund, as was reported in an article on startupticker.ch. This is a joint initiative of the University of Zurich and the Novartis Venture Fund which supports spin-offs operating in the fields of life sciences and biotechnology in Switzerland. This capital will enable Occlufit to progress with the development of the occluder.
Occlufit was founded in 2018 as a spin-off from the University of Zurich and is based in the city of Zurich. The company is the fifth startup to receive support from the UZH Life Sciences Fund.